Sign up to save your podcasts
Or
Share After Years of Trial and Error, Biotech is Seeing More Successes Than Ever
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
After Years of Trial and Error, Biotech is Seeing More Successes Than Ever
John Crowley, Chairman & Former CEO of Amicus Therapeutics, joins the show to discuss the strides the biotech industry has made in therapies for rare genetic diseases and the industry landscape going forward.
This interview originally aired as part of Wharton Business Daily's Business of Healthcare special.
Hosted on Acast. See acast.com/privacy for more information.
View all episodes
By The Wharton School
4.3
8585 ratings
John Crowley, Chairman & Former CEO of Amicus Therapeutics, joins the show to discuss the strides the biotech industry has made in therapies for rare genetic diseases and the industry landscape going forward.
This interview originally aired as part of Wharton Business Daily's Business of Healthcare special.
Hosted on Acast. See acast.com/privacy for more information.
More shows like This Week in Business
View all
Exchanges
976 Listeners
The McKinsey Podcast
388 Listeners
Coaching for Leaders
1,464 Listeners
HBR IdeaCast
1,831 Listeners
Cold Call
196 Listeners
WSJ Minute Briefing
673 Listeners
Wall Street Breakfast
1,037 Listeners
HBS Managing the Future of Work
107 Listeners
Inside the Strategy Room
169 Listeners
Me, Myself, and AI
105 Listeners
Coaching Real Leaders
668 Listeners
The So What from BCG
221 Listeners
HBR On Strategy
77 Listeners
HBR On Leadership
159 Listeners
Stanford GSB: View From The Top
21 Listeners